AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages

  Ma, Jun ^a   Luo, Di Xian ^a,b   Huang, Chenfei ^a   Shen, Yi ^a   Bu, Yiwen ^a   Markwell, Stephen ^a   Gao, John ^c   Liu, Jianghua ^d   Zu, Xuyu ^d   Cao, Zhe ^d   Gao, Zachary ^a   Lu, Fengmin ^e   Liao, Duan Fang ^d,f   Cao, Deliang ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

^c MEMORIAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH CHINA   (China)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^f HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

aldo keto reductase 1B10; breast cancer; disease related survival; prognostic marker; serum marker

Indexed keywords

ALDO KETO REDUCTASE 1B10; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; OXIDOREDUCTASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; AKR1B10 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENT CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALDEHYDE REDUCTASE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864151893     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27618     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008; 26: 1059-65.
3. Tan AR, Swain SM,. Therapeutic strategies for triple-negative breast cancer. Cancer J 2008; 14: 343-51.
4. Morris SR, Carey LA,. Molecular profiling in breast cancer. Rev Endocr Metab Disord 2007; 8: 185-98.
5. Cao D, Fan ST, Chung SS,. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998; 273: 11429-35.
6. Zhong L, Liu Z, Yan R, et al. Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. Biochem Biophys Res Commun 2009; 387: 245-50.
7. Yan R, Zu X, Ma J, et al. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 2007; 121: 2301-06.
8. Zu X, Yan R, Robbins S, et al. Reduced 293T cell susceptibility to acrolein due to aldose reductase-like-1 protein expression. Toxicol Sci 2007; 97: 562-8.
9. Shen Y, Zhong L, Johnson S, et al. Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem Biol Interact 2011; 191: 192-8.
10. Spite M, Baba SP, Ahmed Y, et al. Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem J 2007; 405: 95-105.
11. Martin HJ, Maser E,. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem Biol Interact 2009; 178: 145-50.
12. Quinn AM, Harvey RG, Penning TM,. Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem Res Toxicol 2008; 21: 2207-15.
13. Gallego O, Ruiz FX, Ardevol A, et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA 2007; 104: 20764-9.
14. Crosas B, Hyndman DJ, Gallego O, et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003; 373: 973-9.
15. Ruiz FX, Gallego O, Ardevol A, et al. Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Biol Interact 2009; 178: 171-7.
16. Balendiran GK,. Fibrates in the chemical action of daunorubicin. Curr Cancer Drug Targets 2009; 9: 366-9.
17. Zhong L, Shen, H, Huang, C, et al. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol Appl Pharmacol 2011; 255: 40-7.
18. Wang C, Yan R, Luo D, et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 2009; 284: 26742-8.
19. Ma J, Yan R, Zu X, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 2008; 283: 3418-23.
20. Menendez JA, Lupu R,. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-77.
21. Scuric Z, Stain SC, Anderson WF, et al. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998; 27: 943-50.
22. Hyndman DJ, Flynn TG,. Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim Biophys Acta 1998; 1399: 198-202.
23. Fukumoto S, Yamauchi N, Moriguchi H, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005; 11: 1776-85.
24. Li CP, Goto A, Watanabe A, et al. AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract 2008; 204: 295-304.
25. Kim B, Lee HJ, Choi HY, et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007; 67: 7431-8.
26. Luo D, Huang MC, Ma J, et al. Aldo-keto reductase family 1 member B10 protein is secreted through a lysosome-mediated nonclassical pathway. Biochem J 2011; 438: 71-80.
27. Giltnane JM, Moeder CB, Camp RL, et al. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009; 115: 2400-09.
28. Zu X, Ma J, Liu H, et al. Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression. Breast Cancer Res 2011; 13: R26.
29. Ahmed SA, Gogal RM, Jr, Walsh JE,. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 1994; 170: 211-24.
30. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 2007; 13: 4415-21.
31. LoPachin RM, Gavin T, Petersen DR, et al. Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: nucleophilic targets and adduct formation. Chem Res Toxicol 2009; 22: 1499-508.
32. Jacobs AT, Marnett LJ,. Systems analysis of protein modification and cellular responses induced by electrophile stress. Acc Chem Res 2010; 43: 673-83.
33. Rossi S, Graner E, Febbo P, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003; 1: 707-15.
34. Witters LA, Widmer J, King AN, et al. Identification of human acetyl-CoA carboxylase isozymes in tissue and in breast cancer cells. Int J Biochem 1994; 26: 589-94.
35. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
36. Gupta GP, Massague J,. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
37. Duffy MJ,. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006; 52: 345-51.
38. Levenson VV,. Biomarkers for early detection of breast cancer: what, when, and where? Biochim Biophys Acta 2007; 1770: 847-56.
39. Urruticoechea A, Smith IE, Dowsett M,. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-20.
40. Pritchard KI, Messersmith H, Elavathil L, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008; 26: 736-44.
41. Mariani L, Miceli R, Michilin S, et al. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009; 14: 130-6.
42. Rack B, Schindlbeck C, Juckstock J, et al. Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. Anticancer Res 2010; 30: 1837-41.